Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selective radiation dose escalation and tumor hypoxia in head and neck cancer chemoradiotherapy
2010-021139-15Phase 3Terminated
- Sponsor
- Technical University of Munich Faculty of Medicine
- Start
- Jun 2010
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of misonidazole in head and neck cancer (HNC), sponsored by Technical University of Munich Faculty of Medicine. Primary endpoint: Radiation-induced toxicities (pre-study primary endpoint). Started Jun 2010; status: terminated.
02
Drugs
misonidazole
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on 2010-021139-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021139-15.